Bruker Corporation · NASDAQ:BRKR
Bruker — 2023 J.P. Morgan Healthcare Conference
26 slides from Bruker's conference presentation, Jan 9, 2023
Slide 1: Bruker Corporation 2023 JP Morgan Healthcare Conference
IN N OVATION WITH IN TEG RIT Y Bruker Corporation (Nasdaq: BRKR) 2023 JP Morgan Healthcare Conference Frank H. Laukien Chairman, President & CEO Bruker Corporation January 9, 2023
Slide 2: Safe Harbor Statement
BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
Slide 3: YTD Q3 2022: Robust Organic Growth with Solid Margin Expansion
YTD Q3 2022 FINANCIALS AND FY2023 YTD Q3 2022: Robust Organic Growth with Solid Margin Expansion Solid Q4 2022 Organic Revenue Growth, Strong 2023 Outlook YTD Q3 2022 Financials (all year-over-year) Q4 2022 Preliminary Revenue Estimate and FY 2023 Outlook(1) ❖ Revenue increased $87.9M, up +5.1% ❖ Q4
Slide 4: High-Value Innovation for Strong Revenue and Non-GAAP EPS Growth
DUAL STRATEGY High-Value Innovation for Strong Revenue and Non-GAAP EPS Growth, with Continued Sustainable Margin Improvements Project Accelerate 2.0 Operational Excellence ▪ High Value Innovation & fast ▪ Excellence in operations & revenue and EPS growth logistics ▪ Commercial excellence ▪ Continue
Slide 5: Proprietary TimsTOF Mass Spec Platform Enables 4D Proteomics Revolution
PROTEOMICS AND MULTIOMICS Proprietary TimsTOF® Mass Spec Platform Enables 4D Proteomics™ Revolution Global timsTOF installed base end of 2022 at >600 units © 2023 Bruker 2023 JP Morgan Healthcare Conference | January 9, 2023 | 5
Slide 6: Research Highlight #1: timsTOF mapping of human brain proteome
BREAKOUT OPPORTUNITY - 4D PROTEOMICS Research Highlight #1: timsTOF enabling in-depth mapping of human brain proteome ▪ Dr. Bernard Kuster’s lab at Technical University Munich (TUM) utilizing timsTOF HT for in-depth mapping of human brain proteome ▪ Leading-edge speed & robustness: HT ▪ >2,000 tissu
Slide 7: Research Highlight #2: timsTOF in large-scale plasma proteomics study of COVID-19
BREAKOUT OPPORTUNITY - 4D PROTEOMICS Research Highlight #2: timsTOF in large-scale plasma proteomics study of COVID-19 ▪ Drs. Hanno and Judith Steen at Children’s Hospital, Boston, utilized the timsTOF Pro for plasma proteomics on 4,570 samples from 1,000 patients ▪ Resulting in most complete plasma
Slide 8: Research Highlight #3: timsTOF enabling higher throughput single-cell proteomics
BREAKOUT OPPORTUNITY - 4D PROTEOMICS Research Highlight #3: timsTOF enabling higher throughput single-cell proteomics ▪ timsTOF SCP (Single Cell Proteomics) has a robust workflow and very high sensitivity, with >3,500 proteins identified on average in single cells SCP ▪ Professor Nikolai Slavov at N
Slide 9: Expanding Portfolio for Spatial Biology & Single-Cell Omics
SPATIAL BIOLOGY & SPATIAL MULTIOMICS Expanding Portfolio for Spatial Biology & Single-Cell Omics: Canopy CellScape™ and MALDI HiPLEX-IHC™ True single-cell & subcellular resolution ❖ CellScape™ spatial single-cell proteomics ❖ MALDI HiPLEX-IHC™ spatial tissue multiomics ❖ Highly multiplexed spatial o
Slide 10: Canopy CellScape ChipCytometry
SPATIAL SINGLE-CELL BIOLOGY Canopy CellScape™ ChipCytometry Differentiated Quantitative Performance for Spatial Single-Cell Proteomics Highest Optical Resolution High Dynamic Range High Throughput Open-Source Antibodies Quantitative AI Walk-away Automation Pre-validated Panels 8-log dynamic range 8X
Slide 11: Human breast carcinoma
Human breast carcinoma 100-plex study on Canopy CellScape™ Image on right shows FOV below. - CD8 and CD4 illustrate T cells - CD20 marks B cells - CD56 shows NK cells - pan-Cytokeratin highlights epithelial cells - CD340(Her2) marks tumor cells. © 2023 Bruker 2023 JP Morgan Healthcare Conference | J
Slide 12: Thoughtful M&A and Majority Investment Strategy
BRUKER M&A STRATEGY Thoughtful M&A and Majority Investment Strategy: Accelerate Project Accelerate 2.0 initiatives and enhance core business 1. Enhance and expand life- 2. Enter adjacent growth markets 3. Enter attractive new markets science research solutions with strong synergies with strong secul
Slide 13: Expansion into Neuroscience Research solutions
SPATIAL & CELL BIOLOGY: Expansion into Neuroscience Research solutions Neuroscience Research Solutions #1 Tech Pioneer Innovation Pioneering life brain mapping technology to directly 2021 The Scientist 2016 WEF observe neuronal ensembles and brain circuits during real-time behavior 1,000+ 600+ Sites
Slide 14: Mapping Life Brain Circuits in Action is Key to Preclinical Neuroscience Models
SPATIAL & CELL BIOLOGY: Expansion into Neuroscience Research solutions Mapping Life Brain Circuits in Action is Key to Developing Mechanistic and Predictive Preclinical Neuroscience Models “We can measure the activity of a single neuron, or we can look at the whole brain. But a big intermediate zone
Slide 15: Inscopix Platform as an Integrated Neuroscience Research Solution
SPATIAL & CELL BIOLOGY: Expansion into Neuroscience Research solutions Inscopix Platform as an Integrated Neuroscience Research Solution Mesoscale Life Brain- Data Acquisition Data Processing Mapping Platform Ready-to- Proview™ Proview™ Image Virus Integrated Lens Express Probe Inscopix Data Process
Slide 16: Biognosys: Transformative insights from discovery to clinic
Biognosys Transformative insights from discovery to clinic © 2023 Bruker 2023 JP Morgan Healthcare Conference | January 9, 2023 | 16
Slide 17: Biognosys Makes Proteome Accessible
PROTEOMICS CRO SERVICES, SOFTWARE AND CONSUMABLES Biognosys Makes Proteome Accessible by Covering Needs of a Wide Range of Biomarker and Biopharma Researchers Bruker acquired >80% of Biognosys in January 2023. Biognosys 2022 revenues ~$15M. We expect DD growth, strong synergies, accretive to EBIT in
Slide 18: Biognosys By The Numbers
PROTEOMICS CRO SERVICES, SOFTWARE AND CONSUMABLES Biognosys By The Numbers Co-founded by proteomics pioneer > 14 Years of Proteomics Innovation Ruedi Aebersold (ETH Zurich) Strong scientific foundation and R&D- > 50% PhD Scientists, ~80 employees centric mindset 58 Granted International Patents Inve
Slide 19: Faster Growth from Six High-Growth, High-Margin Initiatives
PROJECT ACCELERATE 2.0 DELIVERS Faster Growth from Six High-Growth, High-Margin Initiatives & Operational Excellence Unbiased 4D-Proteomics & Unbiased Epiproteomics, Functional Consumables, Scientific Proteomics & Structural Biology, SCP Software & Aftermarket Multiomics Proteomics, PTMs, multiomic
Slide 20: Appendix
Appendix 20
Slide 21: Disclosures about Q4 2022 and 2023 commentary on slide 3
BRUKER CORPORATION Disclosures about Q4 2022 and 2023 commentary on slide 3 ▪ Reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is available at the end of this presentation. ▪ Because the Company’s financial statements for the fiscal year ended December 31,
Slide 22: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2017 2018 2019 2020 2021 2021 2022
Slide 23: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2017 2018 2019 2020 2021 2021 2022
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2017 2018 2019 2020 2021 2021 2022
Slide 25: YTD Q3 2022 Reconciliation of GAAP to Organic Revenue Growth
BRUKER CORPORATION YTD Q3 2022 Reconciliation of GAAP to Organic Revenue Growth (Unaudited) Nine Months Ended (in millions) September 30, 2022 Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth Total Bruker GAAP Revenue as of Prior Comparable Period $ 1,734.4 Non-GAAP Adjustmen
Slide 26: 2023 JP Morgan Healthcare Conference
2023 JP Morgan Healthcare Conference